ASTRO 2022 | Phase III study of de-escalated adjuvant radiation therapy for HPV-associated oropharynx cancer

David Routman, MD, Mayo Clinic, Rochester, MN, discusses the rationale and study design of the MC1675 trial (NCT02908477) that evaluated the use of de-escalated adjuvant radiation therapy (DART) compared to the standard of care adjuvant radiation therapy for HPV-associated oropharynx cancer after surgery. The Phase III randomized study found that a shortened treatment duration plus reduced treatment dose does not reduce locoregional control for appropriately selected patients compared to the standard treatment. The risk of toxicity is also likely reduced. Follow up is ongoing. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.